Boston, MA, United States of America

David Shima

This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: Ophthotech Corporation. Active years: 2010-2014.

USPTO Granted Patents = 4 

Average Co-Inventor Count = 3.0

ph-index = 4

Forward Citations = 66(Granted Patents)


Company Filing History:


Years Active: 2010-2014

Loading Chart...
4 patents (USPTO):Explore Patents

Title: David Shima: Innovator in Ocular Therapy

Introduction

David Shima is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of ocular therapy, particularly in the treatment of neovascular disorders. With a total of 4 patents to his name, Shima's work has the potential to impact many patients suffering from these conditions.

Latest Patents

One of David Shima's latest patents focuses on combination therapy for the treatment of ocular neovascular disorders. This invention features methods for treating patients diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist. Additionally, the invention includes a pharmaceutical composition containing both antagonists for the treatment or prevention of neovascular disorders.

Career Highlights

Shima is currently associated with Ophthotech Corporation, where he continues to innovate in the field of ocular health. His work is characterized by a commitment to developing effective therapies that address complex medical challenges.

Collaborations

David Shima has collaborated with notable colleagues, including Perry Calias and Anthony P Adamis. These partnerships have further enhanced his research and development efforts in ocular therapies.

Conclusion

David Shima's contributions to ocular therapy through his innovative patents and collaborations highlight his dedication to improving patient outcomes. His work continues to pave the way for advancements in the treatment of neovascular disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…